Health Canada Approves IMCIVREE for Acquired Hypothalamic Obesity
What happened
Health Canada approved IMCIVREE (setmelanotide) for an additional indication: weight management in adult and pediatric patients aged four years and older with acquired hypothalamic obesity (HO). This follows the drug's initial approval in 2023 for patients with obesity due to Bardet-Biedl syndrome or specific genetic deficiencies. Jennifer Lee, Executive Vice President at Rhythm, stated the approval provides a new treatment option for eligible patients in Canada.
From baystreet.ca
Why it matters
The approval expands the market reach of IMCIVREE in Canada. This new indication targets acquired hypothalamic obesity, a rare and complex MC4R pathway disease, providing a new commercial opportunity for Rhythm.
From baystreet.ca
Who's involved
- Health CanadaDepartment that formally approved IMCIVREE for the new indication.
- RhythmManufacturer of IMCIVREE, which received the new approval.
- Jennifer LeeExecutive Vice President at Rhythm, who commented on the approval.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- RhythmSpeculative
Rhythm could see increased revenue from expanding its market access to acquired hypothalamic obesity in Canada.
Keep exploring
The entities involved
-
Health Canada
Department of the Canadian Government that oversees public health
-
Rhythm
Japanese global corporate group based in Saitama, Japan
Nothing else this week.
-
Jennifer Lee
public health researcher,
Nothing else this week.